The ABC-06 clinical trial established active-symptom control + oxaliplatin/5-FU chemotherapy (FOLFOX) as the standard of care treatment after Cisplatin and Gemcitabine for advanced biliary cancers. Dr Angela Lamarca (Fundación Jiménez Diaz University Hospital, Madrid, Spain) joins touchONCOLOGY to discuss the efficacy and safety of second-line active- symptom-control with FOLFOX, and the quality of life and value of health results.
The abstract entitled ‘Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial‘ Abstract 54MO, was presented at European Society for Medical Oncology (ESMO) 2022.
- What did the ABC-06 study teach us about the efficacy and safety of second-line active- symptom-control (ASC) with oxaliplatin/5-FU chemotherapy (FOLFOX) in the treatment of advanced biliary cancers (ABC)? (0:31)
- What was the rationale for this analysis of the ABC-06 data? (1:25)
- What were the findings of the analysis? (2:50)
- What questions remain unanswered and what further research is planned? (3:09)
Disclosures: Angela Lamarca has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Gastrointestinal Cancers
Upper gastrointestinal cancer highlights – KEYNOTE-585, KEYNOTE-811, MATTERHORN and SANO: Ken Kato, ASCO 2023
Data released from the KEYNOTE-585 (NCT03221426), KEYNOTE-811 (NCT03615326), MATTERHORN (NCT04592913) and SANO (NCT05491616) trials, were some of the most anticipated results and highlights in upper gastrointestinal cancer presented at EMSO 2023. To summarise the findings from these key studies and their impact on the treatment of upper gastrointestinal cancers we caught up with esophageal oncologist […]
Thierry André, ASCO 2023: The SOLISTICE phase III study, trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer
The SOLISTICE phase III study aimed to assess trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer. In this touchONCOLOGY interview, we speak with Dr Thierry André (Hôpital Saint-Antoine, Paris, France) to discuss the rationale for the use of trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer, the secondary endpoint of overall survival and the key […]
Michael K Gibson, ASCO 2023: Highlights in upper GI oncology
touchONCOLOGY spoke with editorial board member Michael K Gibson (Vanderbilt University, Nashville, TN, USA) to discuss his highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023 in the field of upper GI oncology, including the phase 3 ATTRACTION-5 study and a randomized, phase II study assessing toripalimab for the treatment […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!